Developing a Solution to Cure Corneal Blindness

Limbustem is a company developing an innovative therapy for limbal stem cell deficiency (LSCD), which can cause corneal blindness. Their product, Limbustem PRO AMEX, is an in vitro cultured limbal epithelial cellular therapy aimed at restoring vision and improving patients' quality of life. With over 15 years of research, Limbustem's therapy is designed to be more affordable than existing options, making it accessible to more patients. The product is currently preparing for market entry in Europe after successful trials in Türkiye.